BRIEF-Beigene Says Pharmacyclics Litigation Is Not Expected To Affect Operation

Reuters

04-30

BRIEF-Beigene Says Pharmacyclics Litigation Is Not Expected To Affect Operation

April 30 (Reuters) - Beigene 688235.SS:

SAYS PHARMACYCLICS LITIGATION IS NOT HAVING ADVERSE EFFECT ON DEVELOPMENT, SALES OF BRUKINSA IN U.S.
SAYS PHARMACYCLICS LITIGATION IS NOT EXPECTED TO HAVE companyADVERSE EFFECT ON CO'S PRODUCTION, OPERATION

Source text

Further company coverage: 688235.SS

(Reporting by Hong Kong newsroom)

((donny.kwok@thomsonreuters.com; +852 3462 7745;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2531743631"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531743631\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2531743631?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-30 08:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531743631","market":"nz","top_or_hot":-1,"title":"BRIEF-Beigene Says Pharmacyclics Litigation Is Not Expected To Affect Operation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Beigene Says Pharmacyclics Litigation Is Not Expected To Affect Operation</title></head><body><p><span>April 30 (Reuters)</span><span> - </span>Beigene <span>688235.SS</span>:</p><ul><li><p>SAYS PHARMACYCLICS LITIGATION IS NOT HAVING ADVERSE EFFECT ON DEVELOPMENT, SALES OF BRUKINSA IN U.S.</p></li><li><p>SAYS PHARMACYCLICS LITIGATION IS NOT EXPECTED TO HAVE companyADVERSE EFFECT ON CO'S PRODUCTION, OPERATION</p></li></ul><p>Source text</p><p>Further company coverage: <span>688235.SS</span></p><p> (Reporting by Hong Kong newsroom)</p><p> ((donny.kwok@thomsonreuters.com; +852 3462 7745;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Beigene Says Pharmacyclics Litigation Is Not Expected To Affect Operation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Beigene Says Pharmacyclics Litigation Is Not Expected To Affect Operation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-30 08:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Beigene Says Pharmacyclics Litigation Is Not Expected To Affect Operation</title></head><body><p><span>April 30 (Reuters)</span><span> - </span>Beigene <span>688235.SS</span>:</p><ul><li><p>SAYS PHARMACYCLICS LITIGATION IS NOT HAVING ADVERSE EFFECT ON DEVELOPMENT, SALES OF BRUKINSA IN U.S.</p></li><li><p>SAYS PHARMACYCLICS LITIGATION IS NOT EXPECTED TO HAVE companyADVERSE EFFECT ON CO'S PRODUCTION, OPERATION</p></li></ul><p>Source text</p><p>Further company coverage: <span>688235.SS</span></p><p> (Reporting by Hong Kong newsroom)</p><p> ((donny.kwok@thomsonreuters.com; +852 3462 7745;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0307460666.USD","symbol_name":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nL4N3R801B:1","article_id":"2531743631","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531743631","pubTimestamp":1745972342,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Beigene Says Pharmacyclics Litigation Is Not Expected To Affect OperationApril 30  - Beigene 688235.SS:SAYS PHARMACYCLICS LITIGATION IS NOT HAVING ADVERSE EFFECT ON DEVELOPMENT, SALES OF BRUKINSA IN U.S.SAYS PHARMACYCLICS LITIGATION IS NOT EXPECTED TO HAVE companyADVERSE EFFECT ON CO'S PRODUCTION, OPERATIONSource textFurther company coverage: 688235.SS  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688235":"百济神州","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK1588":"回港中概股","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK0239":"医药制造","BK1500":"做空集合股","06160":"百济神州","BK1161":"生物科技","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1583":"高瓴概念"},"translate_title":"简报-百济神州表示Pharmacyclics诉讼预计不会影响运营","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":0.9,"06160":0.9},"content_text":"BRIEF-Beigene Says Pharmacyclics Litigation Is Not Expected To Affect OperationApril 30 (Reuters) - Beigene 688235.SS:SAYS PHARMACYCLICS LITIGATION IS NOT HAVING ADVERSE EFFECT ON DEVELOPMENT, SALES OF BRUKINSA IN U.S.SAYS PHARMACYCLICS LITIGATION IS NOT EXPECTED TO HAVE companyADVERSE EFFECT ON CO'S PRODUCTION, OPERATIONSource textFurther company coverage: 688235.SS (Reporting by Hong Kong newsroom) ((donny.kwok@thomsonreuters.com; +852 3462 7745;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}